Cognition Therapeutics, Inc., a biopharmaceutical company headquartered in Pittsburgh, United States, has been making strides in the healthcare sector with its focus on developing small molecule therapeutics. These therapeutics are specifically designed to target toxic proteins that contribute to cognitive decline, particularly in Alzheimer’s disease and other degenerative brain disorders. The company’s innovative approach aims to address the unmet medical needs associated with these debilitating conditions.

As of October 13, 2025, Cognition Therapeutics’ stock was trading at a close price of $1.74 on the Nasdaq exchange. This price reflects a significant fluctuation over the past year, with the stock reaching a 52-week high of $3.83 on August 24, 2025, and a 52-week low of $0.222 on May 27, 2025. These variations highlight the dynamic nature of the biopharmaceutical market and the challenges faced by companies in this sector.

With a market capitalization of approximately $153.5 million, Cognition Therapeutics is a relatively small player in the healthcare industry. However, its global orientation and commitment to addressing critical health issues position it as a noteworthy entity in the field of neurodegenerative disease research. The company serves its international customer base through its official website, www.cogrx.com , and maintains its presence on the Nasdaq stock exchange, facilitating access for investors and stakeholders worldwide.

Cognition Therapeutics’ strategic focus on small molecule therapeutics is particularly significant given the increasing prevalence of Alzheimer’s disease and other cognitive disorders. By targeting the underlying toxic proteins responsible for cognitive decline, the company aims to develop treatments that could potentially slow or halt the progression of these diseases. This approach not only underscores the company’s dedication to innovation but also its potential to make a meaningful impact on public health.

In summary, Cognition Therapeutics, Inc. continues to pursue its mission of discovering and developing therapeutics for cognitive decline, leveraging its expertise in small molecule drug discovery. Despite the challenges inherent in the biopharmaceutical industry, the company’s focus on addressing critical health issues and its global reach position it as a key player in the ongoing battle against neurodegenerative diseases.